TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients
The purpose of this study is to determine the maximum tolerated dose of the TLC D-99 combined with ifosfamide and then the efficacy of this combination in terms of overall response rate, time to progression and time of response
Sarcoma, Soft Tissue
DRUG: combination of TLC D-99 and Ifosfamide
Phase I: Maximum Tolerated Dose (MTD) of combination of TLC D-99 and Ifosfamide, Definition of TDL|Phase II: Response rate (CR/PR or SD), Tumor assessment
Phase II: time to progression, duration of response, overall survival, Tumor assessment, follow-up
The Maximum Tolerated Dose of the combination was determined and the Phase I terminated.

Then, Phase II study started.